- Home
- Industry Reports
- Healthcare
- Pharmaceuticals
- Europe Vaccine Adjuvants Market – Size, Outlook, Trends and Forecast (2024 – 2032)
An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities.
Europe Vaccine Adjuvants Market Segments Size & Growth:
Europe vaccine adjuvants market size is projected to reach approximately $197.21 million by the end of 2024 with a CAGR of close to 12.48% from $124.28 million in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include increasing use of recombinant subunit and synthetic vaccines, Unmet Vaccine market needs for specific diseases, technological innovations and Expanding government recommendations for immunisations. However, lack of scientific awareness of adjuvants, Funding/cost of developing a new adjuvant, strict regulatory factors, high toxicity adjuvants and side effects of adjuvants are thereby hampering the market growth.
Europe Vaccine Adjuvants Market Segments Share:
The type which comprises Aluminium Salts categorises Europe vaccine adjuvants market, Tensoactive Adjuvants, Adjuvant Emulsions, Bacteria derived Adjuvants, Liposome Adjuvants, Carbohydrate Adjuvants, among others. Among them, Adjuvant Emulsions holds the most significant share in the market. By Route of administration into oral, intradermal, and intranasal. Among them, intranasal segment holds the most significant share in the market. By the mechanism of action into active immunostimulants, carriers, and vehicle adjuvants. By Geography, Germany and U.K are expected to experience the highest growth in the forecast period due to increasing awareness in the region.
Europe Vaccine Adjuvants Market Trends:
- Leading global biotherapeutics company CSL Limited (ASX: CSL), officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben Carroll, MP.
- Novavax, Inc. announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization will continue.
- Agenus Inc., an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR).
Europe Vaccine Adjuvants Market Research Report:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
The primary market players, such as
- MPV Technologies
- Avanti Polar Lipids
- Agenus, Inc.
- Invivogen
- SPI Pharma, Inc.
1.Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Expanding government recommendations for immunizations
4.1.2 Increasing use of recombinant subunit and synthetic vaccines
4.1.3 Unmet Vaccine market needs for certain diseases
4.1.4 Technological innovations
4.2 Restraints
4.2.1 lack of scientific awareness of adjuvants
4.2.2 Funding/cost of developing a new adjuvant
4.2.3 High toxicity adjuvants
4.2.4 Side effects of adjuvants
4.2.5 strict regulatory factors
4.3 Opportunities
4.3.1 Pandemic Diseases
4.3.2 Combination Adjuvants
4.4 Challenges
4.4.1 Identification of Adjuvants
5. Europe Vaccine Adjuvants Market – By Type
5.1 Aluminium Salts
5.2 Tensoactive Adjuvants
5.3 Adjuvant Emulsions
5.4 Bacteria derived Adjuvants
5.5 Liposome Adjuvants
5.6 Carbohydrate Adjuvants
5.7 others
6. Europe Vaccine Adjuvants Market – By route of administration
6.1 oral
6.2 intradermal
6.3 intranasal
7. Europe Vaccine Adjuvants Market – By mechanism of action
7.1 active immunostimulants
7.2 carriers
7.3 vehicle adjuvants
8. Europe Vaccine Adjuvants Market – By Country
8.1. Introduction
8.2.UK
8.3. Germany
8.4. Italy
8.5 Rest of Europe
9. Company Profiles
9.1 OZ Biosciences
9.2 CSL Limited
9.3 SPI Pharma Inc.
9.4 Invivogen
9.5 Agenus, Inc.
9.6 Seppic
9.7 Brenntag Biosector
9.8 Novavax Inc.
9.9 Avanti Polar Lipids
9.10 MPV Technologies
10. Europe Vaccine Adjuvants Market – Competitive Landscape
10.1 Market Share Analysis
10.2 Strategies Adopted by top companies
10.3 Mergers, Acquisitions, Collaborations & Agreements
11. Market Insights
11.1 Insights of Industry Experts
11.2 Investment Opportunities
11.3 Analyst Opinion
12. Appendix
12.1 List of Tables
12.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Regional Report
$2,160.00 – $7,200.00
- EUR: €1,991.88 - €6,639.62
- INR: ₹180,043.09 - ₹600,143.64
- AED: د.إ7,927.20 - د.إ26,424.00
- GBP: £1,706.75 - £5,689.16
Description
Regional Reports
Additional information
Report Type | Extensive Report, Miniature report, Snapshot Report |
---|---|
Licence | Single User License, Team License, Corporate License |
An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities.
Europe Vaccine Adjuvants Market Segments Size & Growth:
Europe vaccine adjuvants market size is projected to reach approximately $197.21 million by the end of 2024 with a CAGR of close to 12.48% from $124.28 million in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include increasing use of recombinant subunit and synthetic vaccines, Unmet Vaccine market needs for specific diseases, technological innovations and Expanding government recommendations for immunisations. However, lack of scientific awareness of adjuvants, Funding/cost of developing a new adjuvant, strict regulatory factors, high toxicity adjuvants and side effects of adjuvants are thereby hampering the market growth.
Europe Vaccine Adjuvants Market Segments Share:
The type which comprises Aluminium Salts categorises Europe vaccine adjuvants market, Tensoactive Adjuvants, Adjuvant Emulsions, Bacteria derived Adjuvants, Liposome Adjuvants, Carbohydrate Adjuvants, among others. Among them, Adjuvant Emulsions holds the most significant share in the market. By Route of administration into oral, intradermal, and intranasal. Among them, intranasal segment holds the most significant share in the market. By the mechanism of action into active immunostimulants, carriers, and vehicle adjuvants. By Geography, Germany and U.K are expected to experience the highest growth in the forecast period due to increasing awareness in the region.
Europe Vaccine Adjuvants Market Trends:
- Leading global biotherapeutics company CSL Limited (ASX: CSL), officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben Carroll, MP.
- Novavax, Inc. announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization will continue.
- Agenus Inc., an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR).
Europe Vaccine Adjuvants Market Research Report:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
The primary market players, such as
- MPV Technologies
- Avanti Polar Lipids
- Agenus, Inc.
- Invivogen
- SPI Pharma, Inc.
1.Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Expanding government recommendations for immunizations
4.1.2 Increasing use of recombinant subunit and synthetic vaccines
4.1.3 Unmet Vaccine market needs for certain diseases
4.1.4 Technological innovations
4.2 Restraints
4.2.1 lack of scientific awareness of adjuvants
4.2.2 Funding/cost of developing a new adjuvant
4.2.3 High toxicity adjuvants
4.2.4 Side effects of adjuvants
4.2.5 strict regulatory factors
4.3 Opportunities
4.3.1 Pandemic Diseases
4.3.2 Combination Adjuvants
4.4 Challenges
4.4.1 Identification of Adjuvants
5. Europe Vaccine Adjuvants Market – By Type
5.1 Aluminium Salts
5.2 Tensoactive Adjuvants
5.3 Adjuvant Emulsions
5.4 Bacteria derived Adjuvants
5.5 Liposome Adjuvants
5.6 Carbohydrate Adjuvants
5.7 others
6. Europe Vaccine Adjuvants Market – By route of administration
6.1 oral
6.2 intradermal
6.3 intranasal
7. Europe Vaccine Adjuvants Market – By mechanism of action
7.1 active immunostimulants
7.2 carriers
7.3 vehicle adjuvants
8. Europe Vaccine Adjuvants Market – By Country
8.1. Introduction
8.2.UK
8.3. Germany
8.4. Italy
8.5 Rest of Europe
9. Company Profiles
9.1 OZ Biosciences
9.2 CSL Limited
9.3 SPI Pharma Inc.
9.4 Invivogen
9.5 Agenus, Inc.
9.6 Seppic
9.7 Brenntag Biosector
9.8 Novavax Inc.
9.9 Avanti Polar Lipids
9.10 MPV Technologies
10. Europe Vaccine Adjuvants Market – Competitive Landscape
10.1 Market Share Analysis
10.2 Strategies Adopted by top companies
10.3 Mergers, Acquisitions, Collaborations & Agreements
11. Market Insights
11.1 Insights of Industry Experts
11.2 Investment Opportunities
11.3 Analyst Opinion
12. Appendix
12.1 List of Tables
12.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.